Losmapimod

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Losmapimod
Accession Number
DB12270
Type
Small Molecule
Groups
Investigational
Description

Losmapimod has been investigated for the prevention of Chronic Obstructive Pulmonary Disease.

Structure
Thumb
Synonyms
Not Available
External IDs
GW-856553X / GW856553 / GW856553X
Categories
UNII
F2DQF16BXE
CAS number
585543-15-3
Weight
Average: 383.467
Monoisotopic: 383.200905252
Chemical Formula
C22H26FN3O2
InChI Key
KKYABQBFGDZVNQ-UHFFFAOYSA-N
InChI
InChI=1S/C22H26FN3O2/c1-13-17(9-15(10-18(13)23)21(28)26-16-6-7-16)19-8-5-14(11-24-19)20(27)25-12-22(2,3)4/h5,8-11,16H,6-7,12H2,1-4H3,(H,25,27)(H,26,28)
IUPAC Name
6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide
SMILES
CC1=C(C=C(C=C1F)C(=O)NC1CC1)C1=CC=C(C=N1)C(=O)NCC(C)(C)C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
11552706
PubChem Substance
347828541
ChemSpider
9727484
BindingDB
50418610
ChEBI
131167
ChEMBL
CHEMBL1088752
Wikipedia
Losmapimod

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAcute Coronary Syndromes (ACS)1
1CompletedTreatmentAtherosclerosis / Cardiovascular Disease (CVD)1
1CompletedTreatmentAtherosclerosis / Chronic Obstructive Pulmonary Disease (COPD) / Rheumatoid Arthritis1
1CompletedTreatmentCardiovascular Disease (CVD)1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2CompletedPreventionChronic Obstructive Pulmonary Disease (COPD)1
2CompletedTreatmentAcute Coronary Syndromes (ACS)1
2CompletedTreatmentAtherosclerosis1
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)4
2CompletedTreatmentDyslipidemias / Healthy Volunteers1
2CompletedTreatmentGlomerulosclerosis, Focal Segmental1
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2CompletedTreatmentPain, Neuropathic1
2CompletedTreatmentRheumatoid Arthritis2
2Not Yet RecruitingTreatmentFacioscapulohumeral Muscular Dystrophy (FSHD)1
2Not Yet RecruitingTreatmentFacioscapulohumeral Muscular Dystrophy 11
2TerminatedTreatmentMajor Depressive Disorder (MDD)1
3CompletedTreatmentAcute Coronary Syndromes (ACS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00393 mg/mLALOGPS
logP3.5ALOGPS
logP3.68ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)13.86ChemAxon
pKa (Strongest Basic)2.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area71.09 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity107.23 m3·mol-1ChemAxon
Polarizability42.79 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Phenylpyridines
Direct Parent
Phenylpyridines
Alternative Parents
3-halobenzoic acids and derivatives / p-Toluamides / Benzamides / Nicotinamides / Benzoyl derivatives / Fluorobenzenes / Aryl fluorides / Heteroaromatic compounds / Secondary carboxylic acid amides / Azacyclic compounds
show 6 more
Substituents
2-phenylpyridine / 3-halobenzoic acid or derivatives / Halobenzoic acid or derivatives / Nicotinamide / Pyridinecarboxamide / Pyridine carboxylic acid or derivatives / Benzamide / Benzoic acid or derivatives / Toluamide / P-toluamide
show 23 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:47 / Updated on June 04, 2019 07:35